{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T08:43:53Z","timestamp":1792226633308,"version":"4.4.0"},"reference-count":11,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T00:00:00Z","timestamp":1571097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title\/>\n                  <jats:p>Platinum-based chemotherapy is commonly associated with toxic sensory neuropathies, but also, although rarely, with Guillain-Barr\u00e9 syndrome (GBS). We describe five patients who developed GBS while receiving platinum-based chemotherapy for a solid tumor and report the five cases published so far. Most patients had received cumulative platinum doses below known neurotoxic levels, and all of them had an optimal outcome after platinum discontinuation, associated in most cases with administration of intravenous immunoglobulin. Clinical presentation, electroneuromyography, and cerebrospinal fluid analysis help clinicians to differentiate GBS from toxic neuropathy. Platinum compounds are the only chemotherapeutic agents used for solid tumors that have been associated to GBS. Thus, we propose that GBS may constitute a non\u2013dose-dependent side effect of platinum drugs and that awareness needs to be raised among oncologists on this rare but potentially life-threatening complication of platinum chemotherapy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2019-0255","type":"journal-article","created":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T19:42:19Z","timestamp":1571168539000},"page":"e194-e197","source":"Crossref","is-referenced-by-count":18,"title":["Guillain-Barr\u00e9 Syndrome During Platinum-Based Chemotherapy: A Case Series and Review of the Literature"],"prefix":"10.1093","volume":"25","author":[{"given":"Evangelia","family":"Pappa","sequence":"first","affiliation":[{"name":"Assistance Publique H\u00f4pitaux de Paris (APHP), Groupe Hospitalier Piti\u00e9-Salp\u00eatri\u00e8re, Service de Neurologie 2-Mazarin et Universit\u00e9 Pierre et Marie Curie-Paris 6, Centre de Recherche de l'Institut du Cerveau et de la Moelle Epini\u00e8re (CRICM), Unit\u00e9 Mixte de Recherche (UMR) S975, Paris, France"},{"name":"INSERM U 975, Centre Nationale de la Recherche Scientifique (CNRS), Unit\u00e9 Mixte de Recherche (UMR) 7225, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Berzero","sequence":"additional","affiliation":[{"name":"Neuroncology Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Mondino Foundation, Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastien","family":"Herlin","sequence":"additional","affiliation":[{"name":"Assistance Publique H\u00f4pitaux de Paris (APHP), Groupe Hospitalier Piti\u00e9-Salp\u00eatri\u00e8re, Service de Neurologie 2-Mazarin et Universit\u00e9 Pierre et Marie Curie-Paris 6, Centre de Recherche de l'Institut du Cerveau et de la Moelle Epini\u00e8re (CRICM), Unit\u00e9 Mixte de Recherche (UMR) S975, Paris, France"},{"name":"INSERM U 975, Centre Nationale de la Recherche Scientifique (CNRS), Unit\u00e9 Mixte de Recherche (UMR) 7225, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Ricard","sequence":"additional","affiliation":[{"name":"OncoNeuroTox Group, H\u00f4pitaux Universitaires Piti\u00e9-Salp\u00eatri\u00e8re-Charles Foix et Percy, Assistance Publique H\u00f4pitaux de Paris (APHP), Paris, France"},{"name":"Department of Neurology, Military Training Hospital Percy, Service de Sant\u00e9 des Arm\u00e9es, Paris, France"},{"name":"Military Health Service Academy of Val-de-Gr\u00e2ce, Service de Sant\u00e9 des Arm\u00e9es, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Tafani","sequence":"additional","affiliation":[{"name":"OncoNeuroTox Group, H\u00f4pitaux Universitaires Piti\u00e9-Salp\u00eatri\u00e8re-Charles Foix et Percy, Assistance Publique H\u00f4pitaux de Paris (APHP), Paris, France"},{"name":"Department of Neurology, Military Training Hospital Percy, Service de Sant\u00e9 des Arm\u00e9es, Paris, France"},{"name":"Military Health Service Academy of Val-de-Gr\u00e2ce, Service de Sant\u00e9 des Arm\u00e9es, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perrine","family":"Devic","sequence":"additional","affiliation":[{"name":"Department of Neurology, Centre Hospitalier Universitaire Lyon Sud, Hospices Civils de Lyon, Pierre-B\u00e9nite, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Maillet","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Centre Hospitalier Lyon Sud, Cancerology Institute of Hospices Civils de Lyon (IC-HCL), Pierre B\u00e9nite, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaina","family":"Borden","sequence":"additional","affiliation":[{"name":"Department of Clinical Neurophysiology, H\u00f4pitaux Universitaires Piti\u00e9-Salp\u00eatri\u00e8re-Charles Foix et Percy, Assistance Publique H\u00f4pitaux de Paris (APHP), Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Viala","sequence":"additional","affiliation":[{"name":"Department of Clinical Neurophysiology, H\u00f4pitaux Universitaires Piti\u00e9-Salp\u00eatri\u00e8re-Charles Foix et Percy, Assistance Publique H\u00f4pitaux de Paris (APHP), Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Maisonobe","sequence":"additional","affiliation":[{"name":"Department of Clinical Neurophysiology, H\u00f4pitaux Universitaires Piti\u00e9-Salp\u00eatri\u00e8re-Charles Foix et Percy, Assistance Publique H\u00f4pitaux de Paris (APHP), Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timoth\u00e9e","family":"Lenglet","sequence":"additional","affiliation":[{"name":"Department of Clinical Neurophysiology, H\u00f4pitaux Universitaires Piti\u00e9-Salp\u00eatri\u00e8re-Charles Foix et Percy, Assistance Publique H\u00f4pitaux de Paris (APHP), Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Weiss","sequence":"additional","affiliation":[{"name":"Neurological Intensive Care Unit, Neurology Department, H\u00f4pitaux Universitaires Piti\u00e9-Salp\u00eatri\u00e8re-Charles Foix et Percy, Assistance Publique H\u00f4pitaux de Paris (APHP), Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitri","family":"Psimaras","sequence":"additional","affiliation":[{"name":"Assistance Publique H\u00f4pitaux de Paris (APHP), Groupe Hospitalier Piti\u00e9-Salp\u00eatri\u00e8re, Service de Neurologie 2-Mazarin et Universit\u00e9 Pierre et Marie Curie-Paris 6, Centre de Recherche de l'Institut du Cerveau et de la Moelle Epini\u00e8re (CRICM), Unit\u00e9 Mixte de Recherche (UMR) S975, Paris, France"},{"name":"INSERM U 975, Centre Nationale de la Recherche Scientifique (CNRS), Unit\u00e9 Mixte de Recherche (UMR) 7225, Paris, France"},{"name":"OncoNeuroTox Group, H\u00f4pitaux Universitaires Piti\u00e9-Salp\u00eatri\u00e8re-Charles Foix et Percy, Assistance Publique H\u00f4pitaux de Paris (APHP), Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,10,15]]},"reference":[{"key":"2021122510032300900_R1","doi-asserted-by":"crossref","first-page":"587","DOI":"10.3109\/0284186X.2014.995775","article-title":"Chemotherapy-induced peripheral neuropathy in patients treated with taxanes and platinum derivatives","volume":"54","author":"Ewertz","year":"2015","journal-title":"Acta Oncol"},{"key":"2021122510032300900_R2","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1093\/brain\/awp219","article-title":"Oxaliplatin-induced neurotoxicity: Changes in axonal excitability precede development of neuropathy","volume":"132","author":"Park","year":"2009","journal-title":"Brain"},{"key":"2021122510032300900_R3","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/brain\/awt285","article-title":"Diagnosis of Guillain-Barr\u00e9 syndrome and validation of Brighton criteria","volume":"137","author":"Fokke","year":"2014","journal-title":"Brain"},{"key":"2021122510032300900_R4","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1097\/00001813-200411000-00010","article-title":"Guillain-Barr\u00e9 syndrome in a patient with metastatic colon cancer receiving oxaliplatin-based chemotherapy","volume":"15","author":"Christodoulou","year":"2004","journal-title":"Anticancer Drugs"},{"key":"2021122510032300900_R5","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1743-7563.2011.01515.x","article-title":"Acute inflammatory demyelinating polyradiculoneuropathy in a patient receiving oxaliplatin-based chemotherapy","volume":"8","author":"Yoon","year":"2012","journal-title":"Asia Pac J Clin Oncol"},{"key":"2021122510032300900_R6","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1179\/joc.2006.18.3.325","article-title":"A case of Guillain-Barr\u00e9 syndrome in a patient with non small cell lung cancer treated with chemotherapy","volume":"18","author":"Cicero","year":"2006","journal-title":"J Chemother"},{"key":"2021122510032300900_R7","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1080\/02841860701877330","article-title":"Weakness and numbness after chemotherapy for metastatic non-seminoma testis: A new neurological complication","volume":"47","author":"Verdonk","year":"2008","journal-title":"Acta Oncol"},{"key":"2021122510032300900_R8","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.ygyno.2005.09.008","article-title":"Guillain-Barre syndrome occurring after adjuvant chemo-radiotherapy for endometrial cancer","volume":"100","author":"Tho","year":"2006","journal-title":"Gynecol Oncol"},{"key":"2021122510032300900_R9","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jinorgbio.2016.06.021","article-title":"Anticancer metal drugs and immunogenic cell death","volume":"165","author":"Terenzi","year":"2016","journal-title":"J Inorg Biochem"},{"key":"2021122510032300900_R10","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.clcc.2016.02.001","article-title":"Oxaliplatin immune-induced syndrome occurs with cumulative administration and rechallenge: Single institution series and systematic review study","volume":"15","author":"Bencardino","year":"2016","journal-title":"Clin Colorectal Cancer"},{"key":"2021122510032300900_R11","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s00415-004-0317-3","article-title":"Piemonte and Valle d'Aosta Register for Guillain-Barr\u00e9 Syndrome. Risk of cancer in patients with Guillain-Barr\u00e9 syndrome (GBS). A population-based study","volume":"251","author":"Vigliani","year":"2004","journal-title":"J Neurol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2019-0255","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2019-0255","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/25\/1\/e194\/41919610\/oncolo_25_1_e194.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/25\/1\/e194\/41919610\/oncolo_25_1_e194.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T10:05:36Z","timestamp":1640426736000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/25\/1\/e194\/6443354"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,15]]},"references-count":11,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,10,15]]},"published-print":{"date-parts":[[2020,1,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2019-0255","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,1,1]]},"published":{"date-parts":[[2019,10,15]]}}}